Background-Vascular adhesion protein-1 (VAP-1) associates to subclinical atherosclerotic manifestations in young people, but its association to incident major adverse cardiovascular events (MACEs) and cardiovascular mortality in a general population is not known. Methods and Results-We used a newly developed ELISA to measure soluble VAP-1 (sVAP-1) levels in 2775 participants (mean age, 60 years) from a prospective cohort study (the FINRISK 2002). During a mean follow-up of 9 years, 265 participants underwent a MACE, and these participants had higher levels of sVAP-1 than those without MACE (868 ng/ mL and 824 ng/mL, respectively, P<0.001). In multivariate-adjusted Cox proportional hazard model including traditional Framingham risk factors (age, sex, systolic blood pressure, cholesterol, high-density lipoprotein cholesterol, smoking, prevalent diabetes mellitus, and antihypertensive treatment), sVAP-1 independently predicted incident MACE (P=0.0046) and MACE mortality (P=0.026). The impact of sVAP-1 in predicting the 9-year absolute risk of MACE was analyzed using integrated discrimination improvement and net reclassification improvement with 10-fold cross-validation. Inclusion of sVAP-1 in the Framingham model improved integrated discrimination improvement (P=0.042), and the clinical net reclassification improvement by correctly reclassifying 9% (P=0.0019) of people in the intermediate risk (5%-20%) group. Conclusions-sVAP-1 associated with increased risk of MACE and MACE mortality in people aged >50 years without prior MACE, and inclusion of sVAP-1 in the risk prediction model improved the clinical net reclassification improvement of incident MACE. Thus, sVAP-1 may be a potential new biomarker for cardiovascular diseases. (Circ Cardiovasc Genet. 2014;7:529-535.)
N early half of the deaths in Europe (47%) are caused by cardiovascular diseases (CVDs). 1 Therefore, many risk prediction models such as the Framingham risk score 2 are frequently used to identify people in risk of getting a disease in next 10 years. Surprisingly however, even half of the people who will have a coronary heart disease have none or only 1 of the 4 conventional risk factors (cigarette smoking, diabetes mellitus, hyperlipidemia, and hypertension). 3, 4 Thus, new predictive markers on top of the conventional risk factors are needed. 5 In particular, the intermediate risk (5%-20%) group still poses a considerable clinical problem in terms of choosing appropriate and cost-effective interventions for right people without overtreating many others. Therefore, emerging focus in CVD risk prediction is to better reclassify people in the intermediate risk group.
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The atherosclerotic process leading to CVDs starts in the childhood, even decades before an actual cardiovascular event. 6 One marker of subclinical atherosclerosis is vascular adhesion protein-1 (VAP-1). 7, 8 It is a transmembrane molecule expressed on the surface of endothelium, smooth muscle cells, and adipocytes. [9] [10] [11] VAP-1 assists leukocytes to adhere to and transmigrate through the vascular endothelia in inflammatory conditions. [12] [13] [14] VAP-1 also has semicarbazide-sensitive amine oxidase (SSAO) activity. It catalyzes a reaction in which primary amines are oxidatively deaminated to corresponding aldehydes, and ammonia and hydrogen peroxide are released. 15 Endothelial dysfunction and activation, as well as lipid oxidation, are typical events in atherosclerosis. [16] [17] [18] [19] In vitro and animal experiments have shown that VAP-1 can promote endothelial dysfunction and atherosclerosis in multiple ways. The oxidase activity of VAP-1 induces the expression of other endothelial adhesion molecules (eg, P-selectin), 20 chemokines (eg, CXCL8), and transcription factors (eg, NF-kB). 21 The products of the catalytic reaction may also be involved in oxidation of lipids, in the production of reactive aldehydes 22 and advanced glycation end products, 23 and at high concentrations they can be directly cytotoxic. The structure of elastic fibers of tunica media is also regulated by VAP-1 in vivo. 24 A soluble form of VAP-1 (sVAP-1) is constitutively formed by proteolytic shedding. 25, 26 The soluble form is enzymatically active, and it can alter leukocyte migration. The sVAP-1 levels are increased in specific inflammatory diseases, such as diabetes mellitus and autoimmune hepatitis, but not in most other inflammatory disorders. 15 We have earlier shown that sVAP-1 is an independent determinant of intima media thickness in a young (30-to 45-year-old) Finnish population. 7 However, no data are available on the association of VAP-1 to incident major adverse cardiovascular events (MACEs) or to cardiovascular mortality in a generally healthy population.
Here we measured sVAP-1 levels with an in-house ELISA in plasma samples of 2775 Finns aged 51 to 74 years (the FINRISK 2002 study). We show that sVAP-1 is an independent risk factor for MACE and MACE mortality and that inclusion of sVAP-1 improves the discrimination and reclassification power of Framingham risk prediction model.
Methods

Study Subjects and Plasma Samples
The study sample consisted of a subsample of 2775 people (aged 51-74 years) from the FINRISK 2002 Study population, which is described in detail elsewhere. 26 In brief, the FINRISK 2002 study participants answered to a health questionnaire, and their blood pressure, serum total cholesterol, high-density lipoprotein (HDL) cholesterol, and C-reactive protein (CRP) were measured when they attended the study. Participants were advised to fast for ≥4 hours before the scheduled blood drawing. Serum and plasma were separated and stored in −70°C. Thereafter, participants have been followed up through record linkages to major national healthcare registers. Local ethical committee has approved the study protocol, and all the study subjects gave a written informed consent.
Measurement of sVAP-1 Concentration
The heparin plasma samples were stored in −70°C until the measurement of sVAP-1 levels was performed with an in-house ELISA. In brief, a 96-well microtiter plate (MaxiSorp, Nunc, 436110, Roskilde, Denmark) was coated with a monoclonal anti-VAP-1 antibody. After overnight incubation at +4°C, the plate was preheated to +37°C and washed with Delfia Platewasher (PerkinElmer, California, USA), using 0.1% Tween-PBS as washing solution. All subsequent steps were performed at room temperature, and all reagents were diluted into the blocking solution (PBS containing 1% gelatin and 1% powdered milk). Samples were centrifuged at 5000 rpm for 3 minutes, and diluted in 1:100. A serial dilution of recombinant human VAP-1 protein (R&D Systems, Minneapolis, USA) was diluted in blocking agent (including VAP-1 depleted plasma in 1:100) to produce a linear standard curve of 6 points. Sequential 1-hour incubations with another biotinylated anti-VAP-1 monoclonal antibody and streptavidin-horseradish peroxidase conjugate (RPN1231V, GEHealthcare, Buckinghamshire, United Kingdom, 1:500 dilution) were performed. Finally, BM Chemiluminescence ELISA substrate for peroxidasebased secondary detection system (Roche Diagnostics, Mannheim, Germany) was added, and the luminescence was measured after 3 minutes with Tecan Infinite M200 plate reader (Tecan Group Ltd, Männedorf, Switzerland). The sVAP-1 values are presented as nanograms of protein in a milliliter of plasma. Interassay and intra-assay coefficients of variability were 9.9% and 5.3%, respectively.
Clinical Outcome
The main outcome studied in this analysis was an incident MACE identified by combining data obtained from the National Hospital Discharge Register, National Causes of Death Register, and National Drug Reimbursement Register. Diagnoses of cardiovascular events in these national registers have been validated. [28] [29] [30] With these national registers, the coverage of follow-up was 100% for participants who continued to live in Finland. Only a negligible fraction of participants (0.5% before December 31, 2010) who had permanently moved abroad were lost to follow-up. All people with a history of previous MACE at the beginning of the study were excluded. MACE was defined to include major coronary heart disease events (n=111, including unstable angina [n=11], acute myocardial infarction [n=55], and coronary revascularization [n=34]), strokes (n=59, including intracerebral hemorrhage [n=7] and cerebral infarction [n=52], but excluding subarachnoid hemorrhages), and heart failure from any cause (n=95). MACE mortality was identified by death caused by MACE.
Statistical Analysis
Continuous variables are shown as mean±SD (age, follow-up time) or as medians with 25th and 75th percentiles (systolic blood pressure, total cholesterol, HDL cholesterol, CRP, and VAP-1). Comparisons of continuous variables between participants without and with MACE, and according to mortality, were done using the Mann-Whitney U test. Spearman rank-order correlation was used to analyze the correlations of continuous variables. The categorical variables (sex, prevalent diabetes mellitus, antihypertensive treatment, current smoking) are expressed as percentages, and the difference between groups was tested with χ 2 test.
When studying the primary association of sVAP-1 to MACE, the population was divided to quartiles according to sVAP-1 values. Log-rank test was used to compare the rates of events in sVAP-1 quartiles and Tukey-Kramer method was used to adjust for the multiple comparisons.
Number of individual risk factors (0-6) for each participant was determined based on the following 6 parameters: systolic blood pressure >140 mm Hg, total cholesterol >5.0 mmol/L, HDL cholesterol <1.0 mmol/L, smoking, antihypertensive treatment, and prevalent diabetes mellitus. The participants were then categorized into a group with 0 to 2 risk factors or 3 to 6 risk factors. Comparison of sVAP-1 values between these 2 groups was done by Mann-Whitney U test.
Values for sVAP-1, systolic blood pressure, total cholesterol, HDL cholesterol, and CRP were natural logarithm (ln) transformed to achieve normal distribution for subsequent analyses. Multivariate Cox proportional hazard models including traditional cardiovascular risk factors 2 (=Framingham model with age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, current smoking, prevalent diabetes mellitus, and antihypertensive treatment as variants) and continuous sVAP-1 were used to estimate the predictive value of lntransformed sVAP-1 for an incident MACE or MACE mortality with time to the incident event as the timescale. In addition, the models were adjusted for the geographic region (Eastern versus Western Finland). Adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated for all variables. For continuous variables, the HRs are shown per 1-SD difference in ln-transformed values. The Cox proportional hazards model fulfilled the proportionality assumption. C-index improvement (C-statistics), integrated discrimination improvement, and net reclassification improvement (NRI) analyses were used to test the discriminative ability of the models. We used category-free NRI and a conventional NRI restricted to the people at intermediate risk for MACE (5%-20% risk for future incident MACE), which is referred to as the clinical NRI. In NRI analyses, the results are shown for accurate reclassifications among all participants, among participants with MACE (events), and among participants without MACE (nonevents). Ten-fold cross-validation was used to control for overfitting. The partition of the data for the 10-fold cross-validation was based on simple random sampling, and it was kept the same throughout the study to obtain comparable results. The selected partition had no significant differences regarding the number of events for the end points studied. Because there was no sex difference in sVAP-1 levels among all participants and because the Framingham model is adjusted for sex, sex-specific analyses were not done. Statistical analyses were done using SAS version 9.2 (SAS Institute Inc, Cary, USA) and R version 2.15 (R Foundation for Statistical Computing, Vienna, Austria). P values <0.05 were considered statistically significant.
Results
Baseline Characteristics
There were 2951 participants in the FINRISK 2002 study, aged >51 years. Plasma samples for sVAP-1 measurements were obtained from 2775 participants. Of them, 248 had had a MACE before the study began and were excluded, leaving 2527 people for analyses. Of all participants, 57.9% were from Eastern Finland (57.4% and 62.3% of participants without and with MACE, respectively, P=0.13). The mean follow-up time was 8.6±1.1 years in the whole population. The mean time to incident MACE was 4.6±2.4 years.
During the follow-up, 265 participants had a MACE. These participants were older and had higher systolic blood pressure and CRP, but lower HDL cholesterol than the participants without events ( Table 1 ). In addition, participants with MACE were more often men and had higher prevalence of smoking, diabetes mellitus, and antihypertensive treatment. During the follow-up, 38 participants died of MACE.
Association of sVAP-1 With Incident MACE
Participants who had a MACE during the average followup of 8.6 years had higher levels of sVAP-1 than those who remained MACE-free (Table 1) . Also, people who had fatal MACE had higher levels of sVAP-1 (862 ng/mL, 25th and 75th percentiles 778 and 1051 ng/mL, respectively) than those without MACE (824 ng/mL, 25th and 75th percentiles 710 and 966 ng/mL, respectively; P=0.040 for Mann-Whitney U test). The cumulative incidence of MACE according to the quartile of sVAP-1 in the whole study population is shown in Figure. The numbers of incident events in the order of increasing quartile of sVAP-1 were 50, 59, 67, and 89 (P=0.0017, log-rank test). When comparing quartiles to each other, the 2 quartiles with lowest sVAP-1 levels (quartiles 1 and 2) differed significantly from the quartile with the highest sVAP-1 level (quartile 4; Tukey-Kramer adjusted P values 0.0012 and 0.024, respectively). The weak associations of sVAP-1 levels to certain traditional risk factors are shown in Tables I and II in the Data Supplement.
sVAP-1 in MACE and MACE Mortality Risk Estimation
The ability of continuous sVAP-1 to predict incident MACE and MACE mortality was estimated with Cox proportional hazard models adjusted for traditional Framingham risk factors (age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, current smoking, prevalent diabetes mellitus, and antihypertensive treatment). In our study population, the Framingham model without sVAP-1 identified age, male sex, systolic blood pressure, smoking, and diabetes mellitus as risk factors for MACE. Although total cholesterol did not remain as an independent predictive factor in this population (probably because a high percentage [79.3%] of all participants had high [>5.0 mmol/L] cholesterol levels), HDL cholesterol was protective, as expected ( Table 2) . When ln-transformed continuous sVAP-1 was included in the model, the same traditional 
Figure.
Higher incidence of major adverse cardiovascular events (MACE) in people with high soluble vascular adhesion protein-1 (sVAP-1). Kaplan-Meier estimates for incident MACE, according to the quartile of sVAP-1 level. P value for log-rank test 0.0017. A MACE was defined as coronary heart disease event, heart failure, or stroke (excluding subarachnoid hemorrhage). The quartiles of sVAP-1 each have 632 or 631 people, and the respective sVAP-1 levels (ng protein/mL plasma) are as follows: quartile 1, <715.8 ng/mL; quartile 2, 715.8 to 828.6 ng/mL; quartile 3, 828.7 to 975.2 ng/mL; and quartile 4, >975.2 ng/mL. risk factors remained significant, and sVAP-1 emerged as an independent risk marker. One-SD increment in natural logarithm of sVAP-1 (accounting for a 30% increase in sVAP-1 concentration) was associated with a 20% (95% confidence interval [CI], 6%-36%) increase in the hazard of incident MACE (P=0.0046) in this fully adjusted model. Moreover, inclusion of hsCRP (HR, 1.23; 95% CI, 1.09-1.39) into the fully adjusted model did not attenuate the predictive power of sVAP-1 (HR, 1.22; 95% CI, 1.08-1.39).
In the Framingham model for fatal MACE (among those who did not have any MACE events at baseline), only age, systolic blood pressure, and smoking out of the traditional risk factors remained significant (Table 3 ). sVAP-1 remained an independent risk marker when included into this model. One-SD increase in natural logarithm of sVAP-1 level increased the risk for fatal MACE by 46% (95% CI, 5%-104%; P=0.026). The HR for fatal MACE was nominally substantially larger than for all MACE, but because of the small number of fatal events, the 95% confidence interval is wide. When sVAP-1 and hsCRP were both in the model for fatal MACE, only sVAP-1 out of these 2 biomarkers remained significant (HR, 1.52; 95% CI, 1.08-2.12 for sVAP-1 and HR, 1.30; 95% CI, 0.92-1.83 for hsCRP).
Discrimination and Reclassification Properties of sVAP-1
Fifty-six percent of the participants who have an incident MACE had none or only 1 or 2 risk factors (when categorized to positive or negative) out of the 6 possible risk factors, including systolic blood pressure, total cholesterol, HDL cholesterol, smoking, antihypertensive treatment, and prevalent diabetes mellitus ( Table III in the Data Supplement). Participants with 0 to 2 risk factors who subsequently have a MACE had higher sVAP-1 levels (838 ng/mL, 25th and 75th percentiles 735 and 1019 ng/mL, respectively) than participants with 0 to 2 risk factors who remained event-free (820 ng/mL, 25th and 75th percentiles 706 and 960 ng/mL, respectively; P=0.037). Among the participants with ≥3 risk factors, the individuals who encountered a MACE also had higher sVAP-1 (882 ng/mL, 25th and 75th percentiles 781 and 1045 ng/mL, respectively) than those without an event (852 ng/mL, 25th and 75th percentiles 725 and 993 ng/mL, respectively; P=0.020). sVAP-1 was Table 2 associated with increased hazard of incident MACE in both groups (0-2 or ≥3 risk factors) in multivariate-adjusted Cox models ( Table IV in the Data Supplement) . Finally, we estimated the ability of sVAP-1 to improve discrimination and reclassification in the whole population by including sVAP-1 to the Cox proportional hazard model adjusted for traditional Framingham parameters. Because these values were obtained from the same data set for which the model was fitted, we used 10-fold cross-validation to assess how well this predictive model performs in practice. The increase in C-statistics (difference±SD of difference, 0.0031±0.0035) was not significant ( Table 4 ). Inclusion of sVAP-1 to the model improved the integrated discrimination improvement (P=0.042; Table 4 ). The category-free NRI for all reclassifications was 0.20 (95% CI, 0.068-0.32; P=0.0025), for events 0.10 (95% CI, −0.015 to 0.22; P=0.086), and for nonevents 0.090 (95% CI, 0.049-0.13; P<0.001). In the clinical NRI analysis, which focuses on people in the intermediate risk category, sVAP-1 significantly improved the clinical NRI for all cases and nonevents, and a borderline improvement for events was seen after 10-fold cross-validation (Table 4 ).
. Association of Traditional Risk Factors and Soluble Vascular Adhesion Protein-1 (sVAP-1) to Incident Major Adverse Cardiovascular Events
Discussion
The main finding of this study is the ability of sVAP-1 to better discriminate people in the intermediate risk category for incident MACE. In our population, out of the 265 MACE that took place during the average 8.6 years of follow-up, 159 events (60.0%) occurred in the intermediate risk group. Even after controlling the prediction model for overfitting by 10-fold cross-validation, sVAP-1 was able to reclassify 9% of people in the intermediate risk group (5%-20% risk for future incident MACE) correctly. In addition, when all participants were divided into groups according to having 0 to 2 or ≥3 out of possible 6 risk factors, sVAP-1 was able to differentiate people having incident MACE in both groups. Additionally, in this community-based cohort, sVAP-1 levels predicted higher risk of MACE and higher risk of MACE mortality (20% and 46% per 1-SD increment in ln-VAP-1 levels, respectively) in models adjusted for all traditional cardiovascular risk factors. These results together suggest that sVAP-1 might be a marker for future risk of incident MACE.
The role of circulating biomarkers in estimating cardiovascular risk has gained increasing attention during the past years, and a few key characteristics for a useful biomarker have been proposed. 5, 31 First, the biomarker should be easy to measure. In this study, the sVAP-1 levels were measured with a semiautomated in-house ELISA, which allows 176 samples to be measured with standard laboratory equipment within 6 hours by a laboratory technician with minimal reagent costs (€59 for 176 samples or €9 for a single sample and €0.3 for each additional sample). Commercially available sVAP-1 ELISA kits with precoated plates are even faster to use. sVAP-1 levels could be also measured with an enzyme activity-based method, 7 which is even cheaper but has more stringent requirements for the sample (storage, anticoagulants, etc). Second, the biomarkers should provide additive information compared with the traditional risk factors, and third, the biomarker results should have an impact on how the patients are treated. In our prospective cohort, 1-time measurement of sVAP-1 level was able to independently predict an increased risk for incident MACE and MACE mortality after adjusting for the traditional risk factors. We showed that with addition of sVAP-1 in the traditional risk prediction model, a substantial proportion (9%) of all people falling into the intermediate risk group was reclassified to lower or higher risk category. This implies that incorporation of sVAP-1 to the risk model would give valuable information to the clinician on how to manage an individual patient. In addition, in our study, we used HRs standardized to 1 SD to allow meaningful comparisons between continuous variables. Therefore, the HR of 1.20 (standardized to 1 SD of natural logarithm of sVAP-1) for sVAP-1 for incident MACE corresponds to the HR of 2.01 for unstandardized ln-transformed sVAP-1, both of which are equivalent with a 30% change in sVAP-1 values.
Although not previously analyzed at a population level, sVAP-1 levels have been earlier reported to associate with certain CVDs in small patient cohorts. Serum sVAP-1 level has been shown to be increased in type 1 and type 2 diabetic patients and to associate with vascular complications in these diseases. 15, 32, 33 Moreover, sVAP-1 predicted cardiovascular mortality in Taiwanese cohort of type 2 diabetic subjects. 34 SSAO activity, presumably mainly generated by sVAP-1, is increased in patients with congestive heart failure, 35 and plasma SSAO level was able to predict mortality in chronic heart failure. 36 The weak associations of sVAP-1 to traditional risk factors of CVDs have been reported previously by us and others 7,37 although they are not always seen in smaller cohorts. 35, 37, 38 Because none of the weak correlations observed in this study was seen among participants with incident MACE, we think that these associations may not be relevant in the pathogenesis of CVDs. Importantly, although sVAP-1 can be induced by certain inflammatory conditions, it does not function as a general marker of inflammation because it shows inverse correlation with CRP, and inclusion of CRP into the Framingham risk model does not affect the predictive power of sVAP-1. Collectively these data and our previous and current results support our hypothesis that sVAP-1 is not only associated to subclinical manifestations of atherosclerosis, but also to the actual MACE events.
As this study demonstrates, sVAP-1 levels are associated to the future risk of having a MACE. VAP-1 may contribute to the pathogenesis of CVDs at several levels. VAP-1 is known to mediate the rolling, firm adhesion, and transmigration of monocytes, granulocytes, and lymphocytes to various tissues such as heart, synovium, gut, liver, and peripheral lymph nodes in an enzyme-activity dependent and enzyme-activity independent manner. 39, 40 Thus, VAP-1 may also contribute to the recruitment of leukocytes to the atheroma. In fact, the gene expression of VAP-1 is upregulated on atherosclerotic plaque formations of carotid arteries. 41 The SSAO activity of VAP-1 may also aggravate atherosclerosis via the catalytic reaction products ammonium, hydrogen peroxide, and aldehydes. The SSAO activity induces damage to endothelial cells in vitro and in vivo through aldehyde interactions with proteins, 22, 42, 43 and it may also be involved in production of advanced glycation end products. VAP-1-generated hydrogen peroxide, in addition, has multiple signaling functions at low concentrations, 20, 21, 44, 45 and at high concentrations it is directly cytotoxic to cells.
We are aware of certain limitations in our experimental settings. Although this is the largest population to date, for which sVAP-1 levels have been determined, the numbers of MACE and especially fatal MACE remain relatively low during the follow-up period. This reduced the statistical power of analyses and prohibited separate analyses of different MACE subgroups. Moreover, because the study was planned to elucidate for the first time the potential of sVAP-1 in predicting CVDs in the general population, a separate validation cohort was not included. In statistical analyses, the effect of this limitation was minimized by rigorous 10-fold cross-validation. Moreover, incorporation of sVAP-1 to the Framingham model did not statistically significantly increase the C-statistics (which measures the discriminative ability of the Cox regression models to distinguish future MACE cases from the noncases). However, Pencina et al 46 have shown that a well-characterized model, such as Framingham, possesses by itself such a good discrimination, that inclusion of any new marker will encounter great difficulties in resulting meaningfully larger AUC. For this reason 2 new measures, integrated discrimination improvement and NRI, have been introduced, both of which significantly improved with inclusion of sVAP-1. Moreover, our data are gathered from 1 white population, and in the future, it will be important to analyze the predictive power of sVAP-1 in different ethnic groups. We also note that in our cohort, a relatively high percentage of incident MACEs took place in the Framingham intermediate risk group (60.0%) and among people who only had 0 to 2 traditional risk factors (56%). However, similar observations have been made in other cohorts. 3, 4 Moreover, correlation of sVAP-1 and other biomarkers of inflammation and/or endothelial dysfunction, such as intercellular adhesion molecule 1, vascular cell adhesion molecule 1, or monocyte chemotactic protein 1, or direct comparisons of the performance of sVAP-1 with these biomarkers in predicting incident MACE have not yet been done. Finally, the clinical use and cost-effectiveness of sVAP-1 determinations in predicting individual risk of incident MACE remain to be determined.
In conclusion, we report here that sVAP-1 is a potential new biomarker for MACE prediction. sVAP-1 improves the risk prediction of incident MACE and MACE mortality when all traditional risk factors have been taken into account. Importantly, inclusion of sVAP-1 into the Framingham model results in a significant improvement in reclassification of people in the clinically relevant 5% to 20% risk category for MACE. Thus, sVAP-1 determinations may provide useful information for early and better identification of patients with increased risk of MACE for optimal medical treatment.
